Incyte Corporation (NASDAQ: INCY) found its shares on the rise Thursday afternoon, following news out of the lab.
Incyte, founded in Palo Alto, California, but now based in Delaware, disclosed that its IDO1 enzyme inhibitor in combo with Merck's anti-PD-1 therapy is “well-tolerated and demonstrated durable clinical responses across multiple solid tumors'”
The company also announced that first data from combo of epacadostat with Bristol-Myers' opdivo showed that combo is “well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors.”
Efficacy data in patients with squamous cell carcinoma of the head and neck, melanoma, ovarian cancer, and colorectal cancer, as well as overall safety data will be highlighted in an oral presentation next week at the American Society of Clinical Oncology annual meeting in Chicago.
ECHO-204 evaluated the safety and efficacy of the epacadostat and nivolumab combination in 241 patients, in tests lasting into last October. In 30 patients with MEL treated with nivolumab plus epacadostat at 100 mg or 300 mg, the combined disease control rate was 73% In patients with SCCHN treated with nivolumab plus epacadostat 300 mg, the preliminary DCR was 70%.
In Phase 1 (dose escalation), 36 patients were enrolled and no dose-limiting toxicities were observed. Among the 205 patients enrolled in Phase 2, the most frequent treatment-related adverse events in patients receiving epacadostat 100 mg BID (70/205) and 300 mg BID were rash, fatigue, and nausea. Rash was the most common
Shares in the drug company climbed $8.46, or 7%, in mid-afternoon trading Thursday to $128.95.
